In GC, VIRMA could interact with the m6A modification site of LINC00958, promoting its enrichment and enhancing its binding with GLUT1 mRNA, thereby increasing the stability of GLUT1 and ultimately promoting aerobic glycolysis in GC cells [70]. The gene discussed is SLC2A1; the disease is gastric cancer.